Abstract P2-06-02: Development of a first-in-class small molecule inhibitor (EC359) targeting oncogenic LIF/LIFR signaling for the treatment of triple negative breast cancer
2016 ◽
Vol 34
(15_suppl)
◽
pp. 1011-1011
◽
2019 ◽
2020 ◽
2019 ◽
2019 ◽
Vol 18
(8)
◽
pp. 1341-1354
◽
2017 ◽
2016 ◽
2021 ◽
Vol 210
◽
pp. 113088